TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
MedPage Today’s Nov. 1 roundup collected eight comments from researchers and clinicians on developments in medicine, including an American Diabetes Association report, clinical trial findings and software problems affecting board exam results. The roundup highlights the speakers’ reactions and concerns; it does not provide full study details or resolve the issues they describe.
MedPage Today published a weekly roundup on Nov. 1 featuring eight comments from clinicians and researchers on recent medical research, health policy and professional issues. The remarks address an American Diabetes Association report, trial results involving aspirin and an investigational cancer drug, and reported software glitches in an internal medicine board exam.
The first quote came from Aaron Kelly, PhD, of the University of Minnesota, responding to the ADA’s final report about five scientists who were removed from this year’s annual meeting. Kelly said, “They’re looking for scapegoats.” The roundup does not include the report’s findings or the scientists’ accounts, so the quote reflects Kelly’s view rather than an independently established explanation for the removals.
Other comments focused on research findings. Hugh Gallagher said that “130 years later” researchers were still working out what to do with aspirin after low-dose aspirin failed to reduce major vascular events in a trial of adults with chronic kidney disease. Separately, Nathalie Gaspar described positive phase III results for an investigational osteosarcoma drug tested in adolescents and adults as “something we have not seen for years.” The roundup does not identify the drug or give the trial’s numerical results.
The remaining remarks covered exam administration, fertility research, policy and medication issues. Aaron Gans, MD, said an “indeterminate” internal medicine board exam score concerned him because of possible data-collection errors after widespread software glitches. Hemant Suryawanshi discussed an AI tool for finding rare sperm in men with azoospermia; Joe Antos described friction in reforming the No Surprises Act; Jay Davis pointed to awareness of possible interactions between GLP-1 drugs and lithium; and Michele Eisenga said an observed rise in hemoglobin and hematocrit among SGLT2 inhibitor users was “likely not just due to hemoconcentration.”
Eight Remarks Span Research and Care
The roundup brings several distinct issues into one snapshot of current medical debate, but the items have different evidentiary weight. The aspirin and osteosarcoma remarks refer to trial findings, while comments about the ADA report, exam scoring and policy describe concerns or interpretations. Those distinctions matter: a short quote can signal a dispute or result, but it cannot substitute for the underlying report, trial data or official explanation.
For readers, the collection points to decisions and questions with potential consequences for researchers, patients and clinicians. The exam software issue, if confirmed and unresolved, could affect confidence in score reporting. Trial findings may inform later research and clinical discussion, but the roundup alone does not establish how they should change care. The comments on medication interactions and fertility technology similarly identify topics for scrutiny, not definitive guidance.
Popular right now
Apple AirPods Pro 3 Wireless Earbuds with Active Noise Cancellation
TCL T7 Series 85-Inch 4K 144Hz QLED Smart Google TV
Sony BRAVIA 5 85-Inch Mini LED 4K HDR Smart TV (K-85XR50)
As an affiliate, we earn on qualifying purchases.
The Roundup’s Eight Topics
MedPage Today describes the piece as a selection of “quotable quotes” heard by its reporters. It was published November 1, 2026, and presents eight short remarks rather than a single report with a shared conclusion. The subjects range from an association’s account of meeting removals to clinical studies and proposals or challenges in medical practice and policy.
The source gives limited background for each item. It identifies the people quoted and, in several cases, their institutions, as well as brief descriptions of the events they were discussing. It does not supply links to the full ADA report, the clinical trials, the exam provider’s response or detailed policy analysis. Accordingly, the developments can be described only at the level given in the roundup.
““They’re looking for scapegoats.””
— Aaron Kelly, PhD, University of Minnesota
Details Behind the Quotes
The roundup does not include the full ADA report or explain the process that led to the five scientists’ removal. It also does not give the aspirin trial’s size, duration or detailed results, or identify the investigational osteosarcoma drug and the specific phase III outcome measures.
Further details are missing about the board exam glitches, the number of candidates affected and whether scores will be reviewed. The source also does not provide performance data for the AI fertility tool, the proposed No Surprises Act changes, or the evidence behind the comments on GLP-1 and lithium or SGLT2 inhibitors and blood measures. These gaps mean the roundup’s statements cannot establish broader conclusions about the issues.
Full Reports Will Add Detail
The next steps are not specified in the roundup. Readers seeking to evaluate the individual developments will need the underlying ADA report, full trial publications or presentations, and statements from the organizations responsible for exam scoring and policy implementation. No follow-up dates or outcomes are provided in the source material.
Until more information is available, the eight comments are best read as attributed reactions and brief descriptions of reported findings. The roundup establishes what the speakers said and the topics they addressed, but leaves open the factual and practical questions behind several of those remarks.
Key Questions
What did MedPage Today publish?
It published a Nov. 1, 2026, roundup of eight comments from clinicians and researchers on medical research, policy and professional issues.
What was the comment about the ADA report?
Aaron Kelly, PhD, said, “They’re looking for scapegoats,” in response to the ADA’s final report about five scientists removed from this year’s annual meeting. The roundup does not give the report’s findings.
What did the aspirin trial find?
As summarized in the roundup, low-dose aspirin failed to reduce major vascular events in a trial of adults with chronic kidney disease. Further trial details are not included.
Were the exam software problems resolved?
The roundup does not say. It reports that Aaron Gans received an “indeterminate” score after widespread software glitches, but gives no account of a review or remedy.
Does the article provide medical advice?
No. It collects comments about research and potential medication interactions; it does not provide treatment recommendations or enough detail to guide individual medical decisions.
Source: medpagetoday.com
